<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
<title>SYNTHENSES, BIOLOGICAL EVALUATION, DOCKING AND ADMET PROFILING OF 4-AMINOANTIPYRINE DERIVATIVES</title>
<link href="http://hdl.handle.net/123456789/2132" rel="alternate"/>
<subtitle/>
<id>http://hdl.handle.net/123456789/2132</id>
<updated>2026-04-15T20:35:53Z</updated>
<dc:date>2026-04-15T20:35:53Z</dc:date>
<entry>
<title>SYNTHENSES, BIOLOGICAL EVALUATION, DOCKING AND ADMET PROFILING OF 4-AMINOANTIPYRINE DERIVATIVES</title>
<link href="http://hdl.handle.net/123456789/2133" rel="alternate"/>
<author>
<name>ERAZUA, Ehimen Annastasia</name>
</author>
<id>http://hdl.handle.net/123456789/2133</id>
<updated>2024-04-26T11:33:44Z</updated>
<published>2023-10-01T00:00:00Z</published>
<summary type="text">SYNTHENSES, BIOLOGICAL EVALUATION, DOCKING AND ADMET PROFILING OF 4-AMINOANTIPYRINE DERIVATIVES
ERAZUA, Ehimen Annastasia
Oxidative-stress, inflammation and glycation processes cause cell damages in the human&#13;
body and may lead to aging and different disease conditions. Drugs that ameliorate oxidative&#13;
stress can solve several disease pathologies. Drug development experiments in the early&#13;
stages are expensive and time-consuming. These constraints could be minimised through&#13;
computational approach. A 4-aminoantipyrine possesses biological properties including&#13;
antioxidant and anti-inflammatory activities. However, information on its application as&#13;
antiglycating agent is sparse. Therefore, this study was aimed at synthesising 4-&#13;
aminoantipyrine derivatives and evaluating their antioxidant, anti-inflammatory,&#13;
antiglycation and toxicity potentials using experimental, docking and ADMET profiling.&#13;
Synthesis of Schiff bases was carried out by condensation of 4-aminoantipyrine with&#13;
different substituted benzaldehydes. Ether derivatives were prepared from 4-&#13;
aminoantipyrine Schiff bases via Williamson ether synthesis. The compounds were purified&#13;
by solvent extraction and characterised using Fourier Transform Infra-Red (FTIR)&#13;
spectroscopy, 1H and 13C Nuclear Magnetic Resonance (NMR) spectroscopy, Mass&#13;
Spectrometry (MS) and X-ray Diffraction (XRD) analysis. Cytotoxicity analysis was&#13;
carried out using brine shrimps and 3T3 mouse fibroblast cell lines. The antioxidant, antiinflammatory and antiglycating activities were evaluated in vitro using 2,2-diphenyl-1-&#13;
picrylhydrazyl radical, oxidative burst assay and human serum albumin solution; and&#13;
compared with gallic acid, ibuprofen and rutin (standards), respectively. Molecular&#13;
descriptors were obtained from Density Functional Theory (DFT) calculations and the&#13;
binding affinity determined by molecular docking. Quantitative Structure-Activity&#13;
Relationship (QSAR) model was used to predict the bioactivity of the compounds. A&#13;
detailed ADMET (adsorption, distribution, metabolism, excretion, and toxicity) screening&#13;
was done in-silico. Data were analysed by descriptive statistics.&#13;
Fifty-eight compounds (thirty Schiff bases and twenty-eight ether derivatives) were&#13;
synthesised out of which 24 were new. A newly synthesised 4-((2-chloro-4-&#13;
fluorobenzylidene)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one, had&#13;
characteristic FTIR ῡmax at 1593 cm-1 for C=N (azomethine bond). The 1H-NMR spectrum&#13;
showed seven methine signals at 9.91, 8.22, 7.55, 7.49, 7.40, 7.36 and 7.34 and two methylvi&#13;
signals at 3.21and 2.47 ppm. The 13C NMR displayed seven quaternary, nine methine and&#13;
two methyl carbons. The MS showed the molecular ion at 343 m/z corresponding to&#13;
C18H15ClFN3O. The XRD showed a monoclinic unit cell and theta of 66.66o. None of the&#13;
compounds was cytotoxic against normal cell lines (Cytotoxicity (3T3Cell-line) %&#13;
inhibition ≤ 25%). Five of the compounds possessed antioxidant activity, with 4-((4-&#13;
hydroxy-3-methoxybenzylidene)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyraz-ol-3-&#13;
one having similar activity (IC50 =111.10±1.80 µM) as gallic acid (IC50 = 111.60±2.40&#13;
µM). Four of the compounds exhibited anti-inflammatory activities with 4-((2,3-&#13;
dihydroxybenzylidene)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one&#13;
having a lower IC50 (0.01±0.02 µM) than that of ibuprofen (11.20±1.90µM). Eight of the&#13;
compounds possessed moderate antiglycation activity (IC50 = 321.16±5.70-&#13;
856.80±2.80µM) when compared to standard (IC50 = 282.40±0.80 µM). The DFT&#13;
calculations and molecular docking confirmed compounds 4-((3,4-&#13;
dihydroxybenzylidene)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3 one and 4-&#13;
((2,3-dihydroxybenzylidene)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one&#13;
with best activities among the tested compounds. The molecular descriptors (EHOMO,&#13;
ELUMO, polarisability, dipole moment and polar surface area) were responsible for the&#13;
biological activities of the compounds. All the synthesised compounds demonstrated&#13;
acceptable outcome in oral bioavailability, lipophilicity, pharmacokinetics, and toxicity&#13;
prediction.&#13;
The synthesised 4-aminoantipyrine derivatives were non-toxic and some possessed antiinflammatory, antioxidant and antiglycation properties making them potential drug&#13;
candidates.
</summary>
<dc:date>2023-10-01T00:00:00Z</dc:date>
</entry>
</feed>
